The biggest clinical trial trends in 2026 are: the new ICH E6(R3) Good Clinical Practice guideline (risk-based quality and data governance); decentralised trial elements such as home visits and telehealth, now covered by FDA guidance and ICH E6(R3) Annex 2; AI moving into trial work under new FDA guidance; more use of real-world data; the EU’s single CTIS system; a surge in obesity and cell- and gene-therapy trials; and in India, CRO registration and faster approval routes. All of them raise demand for people who understand GCP, data and technology.
Key takeaways
- ICH E6(R3) is now the GCP standard; its Annex 2 (decentralised and pragmatic trials) takes effect in the EU from 15 Jan 2027.
- Decentralised elements — telehealth, home visits, eConsent — are now mainstream and regulated.
- FDA’s first AI guidance for drug development (Jan 2025) sets a risk-based credibility framework.
- Cancer is about 30% of recruiting trials; obesity and cell/gene-therapy trials are growing fast.
- India now registers CROs (from April 2025) and can waive some local trials (Rule 101, 2024).
On this page ⌄
Clinical trial trends in numbers
Recruiting interventional trials on ClinicalTrials.gov, checked 8–9 October 2026:
47,170
interventional trials recruiting worldwide.
14,322
recruiting cancer trials — about 30% of the total.
1,077
recruiting CAR-T and gene-therapy trials.
1,175
recruiting obesity trials, including 228 testing semaglutide, tirzepatide or newer GLP-1-type drugs.
1. ICH E6(R3): a new rulebook for running trials
ICH finalised E6(R3) Good Clinical Practice on 6 January 2025. It took effect in the EU on 23 July 2025. It asks teams to build quality in from the start. Checks should focus on what matters most for patient safety and good results. This is called risk-based quality management. It also sets clearer rules for data governance and computer systems.
Annex 2 covers trials run partly outside the hospital, simple real-world trials and real-world data. ICH adopted it on 3 June 2026. It applies in the EU from 15 January 2027 (EMA).
2. Decentralised and hybrid trials become normal
More trial work now happens away from the hospital. Patients join video visits, get nurse visits at home, use local labs, sign consent online and receive the study drug by courier. In September 2024 the US FDA finalised guidance on trials with decentralised elements. It treats these as tools inside a normal trial, not a separate type.
For trial teams, this means new tasks: managing home-visit vendors, remote monitoring and data that arrives from many places.
3. AI moves into everyday trial work
AI now helps pick sites, match patients, code terms, clean data, sort safety reports and draft documents. In January 2025 the FDA published its first draft guidance on AI for drug and biologic decisions. It sets out a seven-step, risk-based credibility check. Sponsors must show an AI model can be trusted for its exact use.
People still review and sign off. Read more in AI in clinical research and AI in medical coding.
4. Data from everywhere: EDC, eCOA, wearables and real-world data
- Cloud EDC is standard, with direct feeds from labs, imaging and IRT systems.
- eCOA and wearables collect symptoms, activity and vital signs from patients’ phones and devices.
- Real-world data from health records and registries supports some trial designs and safety studies.
- Risk-based data review focuses cleaning effort on critical data, in line with ICH E6(R3).
This makes clinical data management more about integrating and reviewing data than typing it. See what is clinical data management.
5. Data privacy and cybersecurity tighten
More digital data means more risk. Trials must follow privacy laws such as the EU GDPR, US HIPAA where it applies, and India’s Digital Personal Data Protection Act, 2023. Systems must also be secure and validated, with audit trails, under 21 CFR Part 11 and ICH E6(R3).
6. One EU system for every trial
Since 31 January 2025, every clinical trial in the EU is governed by the Clinical Trials Regulation and managed through one portal, CTIS. More than 5,000 trials moved across. For global teams in India, this means EU submissions and updates follow one process.
7. New kinds of medicines change trial design
Obesity and metabolic drugs
GLP-1-type medicines drive large, long trials in obesity, diabetes, heart and kidney disease.
Cell and gene therapy
CAR-T and gene therapies need long follow-up and special handling.
Precision oncology
Biomarker-selected patients, master protocols and smaller, targeted groups.
Rare diseases
Small populations and new designs to make the most of every patient.
8. Trials designed around patients
Sponsors now ask patients to help design trials. They cut the number of visits, explain consent in plain words and share results at the end. The 2024 Declaration of Helsinki now says “participant” instead of “subject”. It also stresses community involvement and fair sharing of benefits.
9. Clinical trial trends in India
- CRO registration with CDSCO (Form CT-07B) has been required since 1 April 2025.
- Rule 101 waiver — since a 7 August 2024 order, CDSCO can consider waiving local trials for some drugs already approved in the USA, UK, Japan, Australia, Canada or the EU.
- 490 interventional trials were recruiting at Indian sites on 8 October 2026 — nearly half of them phase 3.
Read the full picture in clinical research in India and our CRO guide.
10. What these clinical trial trends mean for your career
- ICH E6(R3) and risk-based thinking — now expected in monitoring, data and quality roles
- Data skills — EDC, eCOA, reconciliation and, for programmers, CDISC and SAS or R
- Comfort with AI tools — and the judgement to check their output
- Remote and vendor management — for CRAs and trial assistants
- Drug safety and regulations — as new therapies bring new safety questions
Duration
- PG Diploma in Clinical Research
- 7.5 months
Fee
Best for
- PG Diploma in Clinical Research
- CR, CDM, PV and Clinical SAS, with internship
- Advanced Diploma in Clinical Research
- CR, CDM, PV and RA basics, with internship
- Clinical Data Management Training
- EDC and data review skills
FAQs
What are the latest clinical trial trends?
ICH E6(R3) Good Clinical Practice, decentralised trial elements, AI in trial work under new FDA guidance, real-world data, the EU’s CTIS system, a rise in obesity and cell- and gene-therapy trials, and in India, CRO registration and faster approval routes.
What is ICH E6(R3)?
The 2025 revision of the global Good Clinical Practice guideline. It focuses on risk-based quality management and data governance. It took effect in the EU on 23 July 2025, and its Annex 2 on decentralised and pragmatic trials applies in the EU from 15 January 2027.
What is a decentralised clinical trial?
A trial where some activities happen away from the study site — for example telehealth visits, home nursing visits, local labs or drugs shipped to patients. The US FDA finalised guidance on decentralised elements in September 2024.
How is AI used in clinical trials?
For site selection, patient matching, coding, data cleaning, safety case intake and document drafting. FDA’s January 2025 draft guidance asks sponsors to show an AI model is credible for its specific use; people still review the results.
Which therapy areas have the most trials?
Cancer leads — about 30% of recruiting interventional trials on ClinicalTrials.gov in October 2026. Obesity, cardiometabolic disease and cell and gene therapy are growing fast.
Why did this page’s URL change?
We moved it to a year-free address so it can be refreshed every year. The old 2023 address redirects here permanently.